52 generic products enter the market following Lixiana patent expiration
Further price cuts next year... prices could fall by up to 36%
Government to draw up pharmaceutical industry restructuring measures by year-end

As the government lowers prices for generic drugs, 21 domestic pharmaceutical companies are entering the anticoagulant market, worth around 120 billion won annually. Although insurance prices for some products could fall by as much as 36% next year, the companies are seeking to gain an early foothold by leveraging established prescription demand and existing sales networks. However, with numerous pharmaceutical companies entering a limited market at the same time, competition to secure prescription market share is also expected to intensify.


According to the pharmaceutical industry on November 17, the substance patent for Lixiana (generic name: edoxaban), made by Daiichi Sankyo Korea, expired on November 10. Starting November 11, 52 generic products from 21 domestic pharmaceutical companies became eligible for National Health Insurance coverage. Including 12 follow-on drugs with modified salts, the total comes to 64 products from 25 companies. Lixiana generated 121.8 billion won in domestic outpatient prescription sales last year.


Despite Drug Price Cuts, 21 Companies Enter Anticoagulant Market View original image

The competition is drawing attention because it involves a major product subject to the drug-pricing system revised in August 2026. The government lowered the base pricing rate for newly listed generics from 53.55% to 45% of the original drug's price. The rate falls to 36% if a company fails to meet either the requirement for its own bioequivalence test or the requirement to use registered drug substances, and to 28.8% if it fails to meet both. The government also introduced preferential rates of 60% for innovative pharmaceutical companies and 50% for companies designated as leaders in stabilizing supply.


Lixiana is also the first product subject to the newly established multiple-product listing management system. Under the system, if the number of products with the same formulation, including already-listed products and new applications, reaches 14 or more, the prices of newly listed products are further reduced after one year. Twenty-one generics have entered the market for each of Lixiana's 30 mg and 60 mg strengths. The maximum insurance price for standard generics is set to fall by about 15%, from 914 won to 777 won, in November 2027. Prices for products made by innovative pharmaceutical companies could fall by about 36%, from 1,219 won to 777 won, unless their preferential pricing period is extended.


Despite the price cuts, pharmaceutical companies appear to have judged the market to be sufficiently attractive. For medicines such as Lixiana, where prescription demand is already established, companies can secure a certain level of sales by leveraging their existing sales networks. Their preparations for development and regulatory approval, which began before the system was revised, may also have influenced their market entry. “Even if prices fall, the market itself is large, and companies with existing sales networks would have judged the business to be viable if they could secure a certain share of it,” an industry official said.


However, intensifying competition among generic drugs is expected to put greater pressure on pharmaceutical companies' profitability. As price cuts reduce earnings per product, competition to secure prescription market share could become even fiercer. Companies with limited existing sales networks, in particular, may become more reliant on contract sales organizations (CSOs) for pharmaceutical promotion, potentially increasing their sales commission costs.



Alongside drug price cuts, the government is preparing follow-up measures to improve business models centered on generic drugs. Through the public-private Pharmaceutical Industry Innovation Council, launched in September 2026, the Ministry of Health and Welfare is discussing measures including helping generic drug companies scale up and specialize, transition into export-oriented businesses, and strengthen their research and development (R&D) capabilities. Based on these discussions, it plans to draw up measures to strengthen the pharmaceutical industry's competitiveness by the end of 2026.


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing